Game-Changing Clinical Trial Launches for Australia’s Second Deadliest Cancer 1 year ago AnaIn Breaking NewsDeals
ATH434 Shows Significant Promise for Multiple System Atrophy in Landmark Phase 2 Trials 1 year ago AnaIn Clinical TrialsTop Stories
Immunotherapy Duo Shows Major Promise in Early-Stage and Advanced Cancers 1 year ago AnaIn Breaking News
Pioneering CRISPR Therapy Saves Infant With CPS1 Deficiency: A Milestone for Personalised Medicine 1 year ago AnaIn Breaking News
Precision Medicine and Artificial Intelligence Leading Cancer Care Innovations in 2025 1 year ago AnaIn Breaking News
Key Advances in Cancer and Immunotherapy Highlighted at AACR Annual Meeting 2025 1 year ago AnaIn Industry ConferencesPeoplePharma Industry UpdatesTop Stories
New Hope in Rare Diseases: CBL-514 Shows Strong Results at World Orphan Drug Congress 1 year ago AnaIn Industry ConferencesInnovationPeople
Innovent, BriaCell and Pfizer Unveil Cancer Trial Pipeline Updates and Upcoming Data at ASCO 2025 1 year ago AnaIn Pharma Industry Updates
Trodelvy plus Keytruda Shows Promise in First-Line PD-L1+ Triple-Negative Breast Cancer 1 year ago AnaIn Clinical TrialsInnovationLeaders
New Phase III and Preclinical Data Announced 21 April 2025: HER2-Positive Breast Cancer & PROTAC Advances 1 year ago AnaIn Biopharma HighlightsBreakthroughsClinical Trials
New Approvals in April 2025 Signal Advances in Kidney Disease and Giant Cell Arteritis Treatment 1 year ago AnaIn FDA ApprovalsFeatured Analysis
Saroglitazar delivers positive Phase III results in rare liver disease PBC, U.S. filing planned 1 year ago AnaIn Pharma Industry UpdatesTop Stories
FDA approves Dupixent for chronic spontaneous urticaria in ages 12 and up 1 year ago AnaIn Breaking NewsFDA Approvals
FDA updates label for mavacamten after long-term studies show durable benefit in obstructive hypertrophic cardiomyopathy 1 year ago AnaIn BreakthroughsFDA ApprovalsResearch UpdatesTop Stories
Glycomine raises $115 million to push PMM2-CDG therapy into Phase 2b trial 1 year ago AnaIn InvestmentsPeopleVenture Capital
